News

CX-01 is an investigational agent that has the potential to enhance the effectiveness of leukemia treatments by disrupting the adhesion of leukemia cells in the protective bone marrow

Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets. Viamet Pharmaceuticals

The companies have announced a development strategy for M710, a proposed biosimilar to Eylea injection. Eylea is a vascular endothelial growth factor (VEGF) inhibitor developed to treat neovascular

The job cuts will affect employees engaged in the company's commercial and other functions. Allergan said in a US Securities and Exchange Commission filing that it will also terminate nearly 400 open

CNTX-4975 is a non-opioid therapy, which is designed to inject directly into the painful joint. The company has secured funding in the series D financing round led by New

With this financing, Temasek joins new and existing investors including 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative. PEAR is the

The consideration is INR 2,800 million (SEK 351 million1) on a cash and debt free basis whereof INR 600 million (SEK 75 million1) will be paid in newly

Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a marker of classical Hodgkin lymphoma. The FDA is likely to take a call on Adcetris approval by

The Company plans to initiate these studies imminently. Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic